No photo of Richard A Bernstein

View Scopus Profile

Richard A Bernstein

  • 5358 Citations
1994 …2022
If you made any changes in Pure, your changes will be visible here soon.

Personal profile

Research Interests

Neurovascular Critical Care, Stroke, Stroke of unknown cause, stroke in young people, acute stroke therapy, atrial fibrillation, stem cell therapy for stroke.

Certifications and Licenses

Vascular Neurology
Neurology

Training Experience

1997Internship, Mount Sinai Hospital, Illinois
2000Residency, New York Presbyterian Hospital
2001Fellowship, Univ. of CA-San Francisco Med. Ctr.

Education/Academic qualification

MD, PhD, Cornell U Medical Ca

… → 1996

Research interests

  • Stroke

Fingerprint Dive into the research topics where Richard A Bernstein is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 10 Similar Profiles
Stroke Medicine & Life Sciences
Atrial Fibrillation Medicine & Life Sciences
Cerebral Hemorrhage Medicine & Life Sciences
Anticoagulants Medicine & Life Sciences
Hemorrhage Medicine & Life Sciences
Aspirin Medicine & Life Sciences
Blood Platelets Medicine & Life Sciences
Benzimidazoles Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Grants 2003 2022

Stroke AF

Bernstein, R. A. & Caprio, F. Z.

Medtronic, Inc.

7/7/16 → 7/7/22

Project: Research project

Prot # 1160.129: Boehringer Ingelheim Pharmaceuticals, Inc., “GLORIA - AF: Global Registry on Long-Term Oral Anti-thrombotic TReatment In PAtients with Atrial Fibrillation” (Phase II/III)

Bernstein, R. A.

Covance Inc., Boehringer Ingelheim Pharmaceuticals, Inc.

3/29/12 → 3/29/20

Project: Research project

Stroke Trials Network - Regional Coordinating Stroke Centers

Bernstein, R. A., Prabhakaran, S. & Roth, E. J.

National Institute of Neurological Disorders and Stroke

8/1/16 → 7/31/18

Project: Research project

Protocol #1160-189: Randomized, Double-Blind, Evaluation in Secondary Stroke Prevention Comparing the Efficacy and Safety of the Oral Thrombin Inhibitor Dabigatran Etexilate (110 mg or 150 mg, oral b.i.d.) Versus Acetylsalicylic Acid (100 mg oral q.d.) in

Bernstein, R. A. & Caprio, F. Z.

Boehringer Ingelheim Pharmaceuticals, Inc.

8/21/15 → 8/21/19

Project: Research project

A Phase III, Case Series Clinical Study of the Reversal of the Anticoagulant Effects of Dabigatran by Intravenous Administration of 5.0 g Idarucizumab (BI 655075) in Patients Treated with Dabigatran Etexilate who have Uncontrolled Bleeding or Require Emer

Bernstein, R. A.

Boehringer Ingelheim Pharmaceuticals, Inc.

4/6/15 → 4/6/18

Project: Research project

Research Output 1994 2019

Assessment of the End Point Adjudication Process on the Results of the Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trial: A Secondary Analysis

Farrant, M., Easton, J. D., Adelman, E. E., Cucchiara, B. L., Barsan, W. G., Tillman, H. J., Elm, J. J., Kim, A. S., Lindblad, A. S., Palesch, Y. Y., Zhao, W., Pauls, K., Walsh, K. B., Martí-Fàbregas, J., Bernstein, R. A. & Johnston, S. C., Sep 4 2019, In : JAMA network open. 2, 9, p. e1910769

Research output: Contribution to journal › Article

Open Access
clopidogrel
Aspirin
Blood Platelets
Stroke
Research Personnel
36 Citations (Scopus)

Dabigatran for prevention of stroke after embolic stroke of undetermined source

Diener, H. C., Sacco, R. L., Donald Easton, J., Granger, C. B., Bernstein, R. A., Uchiyama, S., Kreuzer, J., Cronin, L., Cotton, D., Grauer, C., Brueckmann, M., Chernyatina, M., Donnan, G., Ferro, J. M., Grond, M., Kallmünzer, B., Krupinski, J., Lee, B. C., Lemmens, R., Masjuan, J. & 5 others, Odinak, M., Saver, J. L., Schellinger, P. D., Toni, D. & Toyoda, K., May 16 2019, In : New England Journal of Medicine. 380, 20, p. 1906-1917 12 p.

Research output: Contribution to journal › Article

Stroke
Aspirin
Hemorrhage
Confidence Intervals
Dabigatran

Evaluation of the effect of sodium–glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR-Reduced trial

on behalf of the EMPEROR-Reduced Trial Committees and Investigators, Executive Committee, National Coordinators, Consulting Statistician, Clinical Events Committee, Scientific Excellence Committee & Data Monitoring Committee, Oct 1 2019, In : European Journal of Heart Failure. 21, 10, p. 1270-1278 9 p.

Research output: Contribution to journal › Article

Open Access
Symporters
Heart Failure
Morbidity
Mortality
Hospitalization
9 Citations (Scopus)

A resident boot camp for reducing door-to-needle times at academic medical centers

Ruff Treiber, I. M., Liberman, A. L., Caprio, F. Z., Maas, M. B., Mendelson, S. J., Sorond, F. A., Bergman, D., Bernstein, R. A., Curran, Y. & Prabhakaran, S., Jun 1 2017, In : Neurology: Clinical Practice. 7, 3, p. 237-245 9 p.

Research output: Contribution to journal › Review article

Needles
Stroke
Tissue Plasminogen Activator
Hospital Emergency Service
Neurology
11 Citations (Scopus)

Cardiac magnetic resonance imaging: A new tool to identify cardioaortic sources in ischaemic stroke

Yaghi, S., Liberman, A. L., Atalay, M., Song, C., Furie, K. L., Kamel, H. & Bernstein, R. A., Jan 1 2017, In : Journal of Neurology, Neurosurgery and Psychiatry. 88, 1, p. 31-37 7 p.

Research output: Contribution to journal › Review article

Stroke
Magnetic Resonance Imaging
Atrial Appendage
Aortic Diseases
Heart Neoplasms